ChromaTwist

Executive Summary

ChromaTwist is a UK-based biotechnology company pioneering the development of large Stokes shift organic fluorescent dyes for advanced biosensing and bioimaging applications. Founded in 2021 and headquartered in Cambridge, the company leverages a highly tunable technology platform to create fluorophores excited by UV and blue light that emit bright, tunable light across the visible spectrum. These novel dyes address critical limitations of conventional fluorescent probes, such as photobleaching, spectral overlap, and limited Stokes shifts, enabling higher sensitivity and multiplexing capabilities in flow cytometry and multiphoton microscopy. By offering superior optical properties and enhanced biocompatibility, ChromaTwist's products aim to accelerate research in cell biology, immunology, and neuroscience, as well as enable more precise diagnostic assays. The company's innovative platform has the potential to disrupt the $5 billion fluorescent probe market, which is dominated by established players. ChromaTwist is poised to capture significant market share by partnering with instrument manufacturers and research reagent distributors. With a strong intellectual property portfolio and an experienced management team, the company is well-positioned for strategic collaborations and commercial traction. Near-term catalysts include securing a Series A funding round to scale manufacturing, launching its first commercial product line for academic and pharma end-users, and forming a co-development agreement with a leading flow cytometry manufacturer.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round Close80% success
• Q4 2026Commercial Launch of First Product Line60% success
• Q1 2027Strategic Partnership with Flow Cytometry OEM50% success